Discussions with leaders: JNM editor-in-chief Johannes Czernin continues a series of inter-views with leaders in nuclear and molecular imaging and therapy with a …

MEP Page - THE JOURNAL OF NUCLEAR MEDICINE, 2019 - Soc Nuclear Med
Prognostic and whole-body MATV/TLG in mCRC: Woff and colleagues explore the
prognostic value of baseline whole-body metabolically active tumor volume and total lesion …

Metabolic active tumor volume and total lesion glycolysis by 18F-FDG PET/CT validated as prognostic imaging biomarkers in chemorefractory metastatic colorectal …

E Woff, A Hendlisz, L Ameye, C Garcia… - Journal of Nuclear …, 2018 - Soc Nuclear Med
This study aimed to validate the prognostic value of baseline whole-body metabolic active
tumor volume (WB-MATV) and total lesion glycolysis (WB-TLG) measured with [18 F] …

Validation of metabolically active tumor volume and total lesion glycolysis as 18F-FDG PET/CT–derived prognostic biomarkers in chemorefractory metastatic …

E Woff, A Hendlisz, L Ameye, C Garcia… - Journal of Nuclear …, 2019 - Soc Nuclear Med
This study aimed to validate the prognostic value of baseline whole-body metabolically
active tumor volume (WB-MATV) and total lesion glycolysis (WB-TLG) measured with 18F …

Whole body Metabolic Tumor Volume combined with early detection of non-response is strongly predictive of overall survival in metastatic colorectal cancer

E Woff, T Kamoun, T Guiot, L Ameye, A Hendlisz… - 2017 - Soc Nuclear Med
421 Objectives: Metastatic colorectal cancer (mCRC) has a poor prognosis, however strong
variation of survival exists among patients, at least partially related to differences in disease …

Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer

E Woff, L Salvatore, F Marmorino… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Stratification of metastatic colorectal cancer (mCRC) patients is mostly based on clinical and
biologic characteristics. This study aimed to validate the prognostic value of 18F-FDG …

[HTML][HTML] The Impact of Complete Metabolic Response in the Treatment of Metastatic Colorectal Cancer

KO Lam, G Cheung, CK Sze, VH Lee, J Tsang… - Annals of …, 2014 - Elsevier
Aim: Molecular imaging with 18F-FDG PET scan is increasingly used for monitoring of
treatment response in metastatic colorectal cancer. While there is no widely accepted …

Baseline FDG PET-CT parameters as predictors of chemoresponse and survival in metastatic colorectal cancer

H El Mansy, C Garcia, A Deleporte, L Ameye… - 2012 - Soc Nuclear Med
1305 Objectives We recently reported that early metabolic response (eMR) measured by the
change of FDG uptake on PET-CT after 1 cycle of polychemotherapy in patients with …

Change in metabolic tumor activity on 18F-FDG PET after a single dose of cetuximab to predict for treatment benefit, PFS, and OS in patients with advanced colorectal …

EJ Van Helden, CW Menke, E Boon, S van Es… - 2017 - ascopubs.org
11519 Background: Despite RAS selection, one third of patients with metastatic RAS wild-
type colorectal cancer (mCRC) do not benefit from anti-EGFR inhibitors. Therefore, an …

Streamline investigators

SA Taylor, S Mallett, S Beare - Diagnostic accuracy of whole-body …, 2019 - europepmc.org
Stuart A Taylor (https://orcid. org/0000-0002-6765-8806)(Professor of Medical Imaging) was
the chief investigator, conceived the study design, contributed to the protocol writing and …

[HTML][HTML] Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer

E Woff, A Hendlisz, C Garcia, A Deleporte… - European journal of …, 2016 - Springer
Introduction The introduction of targeted drugs has had a significant impact on the approach
to assessing tumour response. These drugs often induce a rapid cytostatic effect associated …